Michal Preminger

Brief Sabbatical

2025 - Current

- Catching up on family time - Pursuing passion projects including Renaissance Years and FounderCode Collection Fashion Show. - Maintaining deep involvement in life science and biotech ecosystem through Board, Advisory Board, and mentorship responsibilities.

Member Board Of Directors

2021

Member Board Of Directors

2021

Board Member

2025

Advisory Board Member

2022

LabCentral Funding Lab that supports the fund raising needs of early stage entrepreneurs.

Advisory Board Member

2022

Head of Innovation, East North America

2018 - 2025

In my role as the Head of Johnson & Johnson Innovation in East North America, I led our external innovation team to feed J&J's product pipelines by trendspotting, sourcing and evaluating innovative opportunities and driving R&D partnerships, venture investments, new company creation and startup incubation across J&J's priority therapeutic areas and technology domains. I represented J&J in local and international leaders' forums, build strategic relationships with key stakeholders to drive innovation. I proudly served on as a sponsor, mentor, and accessible resource to emerging innovators and entrepreneurs individually and through programs like Scholars of Oncology Diversity Engagement Program, Venture Forward, Termeer Foundation, Nucleate, MassNextGen, MassBio Drive, Women in Robotics, Women in BIO, Ignite VC and many more. In 2024, I was honored and humbled to receive the inaugural Kendall Square Founders award alongside MIT's Sangeeta Bhatia.

Member of the Scientific Advisory Board

2014 - 2024

At FutuRx, Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines by applying a unique structure of equally balanced partnership among its three founding organizations. FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure. FutuRx management, together with its founders, will establish and fully support the companies via its in-house laboratory and management facility.

Member Board Of Directors

2017 - 2018

https://cgen.com/

Member of the Scientific Advisory Board

2007 - 2018

Prize4Life was founded in 2006 with a singular mission: to accelerate the discovery of treatments and a cure for ALS, a terminal disease whose cause has eluded scientists for over a century. Since then, we have successfully launched and awarded several prizes and programs that have taken us closer to fulfilling that mission. In late 2013, the Board of Directors and management team of Prize4Life took the decision to re-focus its activities to support a single program: the $1M Avi Kremer ALS Treatment Prize4Life. To find out more about this Prize and milestones associated with it, please click here. The rest of Prize4Life's programs, including the award winning PRO-ACT database, the ALS Prediction Algorithm Tool, and ALSGene, will be transferred to its sister organization, Prize4Life Israel, and the ALS Forum will continue as a collaborative program between the two organizations. - See more at: http://www.prize4life.org/#sthash.VclfWE5D.dpuf